A Lymphomimetic Synthetic Immune Niche, Consisting of CCL21 and ICAM1, Accelerates the Expansion of Potent CAR T-cells

A Synthetic Immune Niche (SIN) made from CCL21 and ICAM1 can speed up the growth of effective CAR T-cells, according to a new study. CAR T-cell therapy has been a game-changer for treating certain cancers, but expanding these cells effectively can be challenging. This new research shows that a SIN composed of immobilized CCL21 and ICAM1 can boost the production of powerful CAR T-cells.

To conduct the study, scientists created CD19-directed CAR T-cells from healthy donor blood samples. These cells were then grown on plates coated with CCL21, ICAM1, or left uncoated as a control. The researchers closely examined how the SIN affected the CAR T-cells in terms of expansion, appearance, physical traits, marker expression, and potency.

The results were promising. CAR T-cells exposed to the SIN expanded nine times faster than the control group by day 13, with 77.6% of them being CAR-transduced. This led to a 14.6-fold increase in the actual number of CAR T-cells compared to untreated cultures. The SIN treatment also induced a distinct activated cell appearance, with larger sizes, increased polarity, and higher levels of activation markers CD137 and CD69.

Even after the cells were taken off the SIN, they retained their cytokine secretion and cytotoxic activity, showing that the SIN effect is long-lasting. Furthermore, the SIN-conditioned CAR T-cells showed strong antigen-dependent IFN-gamma secretion and cytotoxicity against CD19-expressing cells.

In conclusion, using a SIN made from immobilized CCL21 and ICAM1 can greatly improve CAR T-cell manufacturing. This simple and scalable strategy can increase the number and potency of CAR T-cells while maintaining their high cytotoxic efficiency.